Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LGVN

LGVN - Longeveron Inc. Stock Price, Fair Value and News

$0.59+0.01 (+1.72%)
Market Closed

7/100

LGVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

LGVN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.46

Target 3M

$0.52

Target 6M

$0.49

LGVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LGVN Price Action

Last 7 days

11.3%

Last 30 days

13.5%

Last 90 days

-29.8%

Trailing 12 Months

-63.1%

LGVN RSI Chart

LGVN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LGVN Valuation

Market Cap

10.8B

Price/Earnings (Trailing)

-507.93

Price/Sales (Trailing)

7.5K

Price/Free Cashflow

-638.41

LGVN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.46

Target 3M

$0.52

Target 6M

$0.49

LGVN Fundamentals

LGVN Revenue

Revenue (TTM)

1.4M

Rev. Growth (Yr)

-82.28%

Rev. Growth (Qtr)

-56.65%

LGVN Earnings

Earnings (TTM)

-21.3M

Earnings Growth (Yr)

-63.41%

Earnings Growth (Qtr)

-43.62%

LGVN Profitability

Operating Margin

74.84%

Return on Equity

-214.15%

Return on Assets

-137.19%

Free Cashflow Yield

-0.16%

LGVN Investor Care

Shares Dilution (1Y)

142.63%

Diluted EPS (TTM)

-0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.2M2.1M1.4M0
2024978.0K1.2M1.9M2.4M
2023961.0K1.1M937.0K709.0K
20221.3M937.0K970.0K1.1M
20210001.3M
20200000
Get all data in R, Python etc through our Historical Stock Data APIs

About Longeveron Inc.

LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
 CEO
 WEBSITEhttps://longeveron.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES19

Longeveron Inc. Frequently Asked Questions

LGVN is the stock ticker symbol of Longeveron Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Longeveron Inc. is 10.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LGVN's fair value in chart for subscribers.

The fair value guage provides a quick view whether LGVN is over valued or under valued. Whether Longeveron Inc. is cheap or expensive depends on the assumptions which impact Longeveron Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LGVN.

As of Wed Jan 28 2026, LGVN's PE ratio (Price to Earnings) is -507.93 and Price to Sales (PS) ratio is 7.54 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LGVN PE ratio will change depending on the future growth rate expectations of investors.